Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (Nasdaq: CHRS) announced on Sept. 24, 2021, that it granted options to purchase 229,500 shares of common stock to newly hired employees, effective Sept. 22, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) announced on Sept. 24, 2021, that it granted options to purchase 229,500 shares of common stock to newly hired employees, effective Sept. 22, 2021. The options have an exercise price of $17.06, matching the closing trading price on the grant date. Among the recipients, a new Senior Vice President received options for 100,000 shares. These grants were made under the Coherus BioSciences 2016 Employment Commencement Incentive Plan, approved to attract new talent.
Details
News Market Reaction – CHRS
The recorded move for CHRS in the trading session of this news was +0.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Sept. 22, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 229,500 shares of the common stock of the Company to newly hired employees with a per share exercise price of
The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. For additional information, please visit www.coherus.com.
Coherus BioSciences Contact Information:
IR Contact
McDavid Stilwell
Coherus BioSciences, Inc.
IR@coherus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.